$ALHC
Alignment Healthcare, Inc. Stock $alhc

$alhc Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000095017022007889 Filed on May 05, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q1
Revenue	$366.5M	$345.5M	$267.1M
YoY Change	18.62%	29.37%	18.9%
Cost Of Revenue	$307.3M	$303.8M	$251.1M
YoY Change	11.98%	20.97%	29.83%
Gross Profit	$59.21M	$41.77M	$15.99M
YoY Change	71.28%	161.26%	-48.82%
Gross Profit Margin	16.16%	12.09%	5.99%
Selling, General & Admin	$61.67M	$74.29M	$64.91M
YoY Change	-13.32%	14.45%	97.99%
% of Gross Profit	104.17%	177.87%	406.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.180M	$3.950M	$3.737M
YoY Change	6.96%	5.7%	4.82%
% of Gross Profit	7.06%	9.46%	23.38%
Operating Expenses	$373.1M	$382.0M	$319.7M
YoY Change	6.78%	19.47%	39.17%
Operating Profit	-$6.648M	-$36.48M	-$52.66M
YoY Change	-83.58%	-30.74%	929.6%
Interest Expense	$4.490M	$4.401M	$4.248M
YoY Change	3.72%	3.6%	2.12%
% of Operating Profit
Other Income/Expense, Net	-$4.932M	-$4.342M	-$4.210M
YoY Change	15.5%	3.14%	-15.07%
Pretax Income	-$11.58M	-$40.82M	-$56.87M
YoY Change	-74.13%	-28.23%	464.67%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.58M	-$40.82M	-$56.87M
YoY Change	-74.13%	-28.23%	464.67%
Net Earnings / Revenue	-3.16%	-11.81%	-21.29%
Basic Earnings Per Share	-$0.06	-$0.23
Diluted Earnings Per Share	-$0.06	-$228.2K	-$303.7K
COMMON SHARES
Basic Shares Outstanding	187.3M	187.1M
Diluted Shares Outstanding		16.21M	12.64M

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$453.2M	$448.8M	$528.4M
YoY Change	-8.37%	-15.06%
Cash & Equivalents	$453.2M	$448.8M	$528.4M
Short-Term Investments
Other Short-Term Assets	$34.34M	$32.83M	$26.77M
YoY Change	7.97%	22.62%
Inventory
Prepaid Expenses
Receivables	$98.03M	$84.53M	$49.46M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$585.6M	$566.2M	$604.6M
YoY Change	-1.23%	-6.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.41M	$31.75M	$28.40M
YoY Change	13.11%	11.77%
Goodwill	$30.63M	$30.63M	$29.30M
YoY Change	4.53%	4.53%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.960M	$4.977M	$2.153M
YoY Change	43.89%	131.17%
Total Long-Term Assets	$81.18M	$80.42M	$74.70M
YoY Change	5.2%	7.67%
TOTAL ASSETS
Total Short-Term Assets	$585.6M	$566.2M	$604.6M
Total Long-Term Assets	$81.18M	$80.42M	$74.70M
Total Assets	$666.8M	$646.6M	$679.3M
YoY Change	-0.49%	-4.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$173.9M	$155.0M	$128.7M
YoY Change	27.4%	20.43%
Accrued Expenses	$24.87M	$23.56M	$21.48M
YoY Change	9.83%	9.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$213.7M	$195.0M	$169.8M
YoY Change	23.01%	14.83%
LONG-TERM LIABILITIES
Long-Term Debt	$153.9M	$152.3M	$145.7M
YoY Change	4.48%	4.48%
Other Long-Term Liabilities	$5.428M	$6.103M	$9.565M
YoY Change	-36.94%	-36.19%
Total Long-Term Liabilities	$153.9M	$152.3M	$145.7M
YoY Change	4.48%	4.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$213.7M	$195.0M	$169.8M
Total Long-Term Liabilities	$153.9M	$152.3M	$145.7M
Total Liabilities	$373.1M	$353.3M	$325.1M
YoY Change	13.16%	8.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$635.1M	-$623.5M	-$436.4M
YoY Change	31.98%	42.86%
Common Stock	$187.0K	$187.0K	$188.0K
YoY Change	-0.53%	-0.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$293.7M	$293.3M	$354.3M
YoY Change
Total Liabilities & Shareholders Equity	$666.8M	$646.6M	$679.3M
YoY Change	-0.49%	-4.82%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$11.58M	-$40.82M	-$56.87M
YoY Change	-74.13%	-28.23%	464.67%
Depreciation, Depletion And Amortization	$4.180M	$3.950M	$3.737M
YoY Change	6.96%	5.7%	4.82%
Cash From Operating Activities	$10.35M	-$11.64M	-$38.11M
YoY Change	-144.16%	-69.46%	74.65%
INVESTING ACTIVITIES
Capital Expenditures	-$5.855M	-$4.914M	-$4.446M
YoY Change	-8.81%	10.53%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$1.213M	$0.00
YoY Change
Cash From Investing Activities	-$5.855M	-$6.127M	-$4.446M
YoY Change	-8.81%	37.81%	19.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$390.6M
YoY Change		-100.0%	189.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-100.0K	0.000	363.7M
YoY Change	-97.17%	-100.0%	176.58%
NET CHANGE
Cash From Operating Activities	10.35M	-11.64M	-38.11M
Cash From Investing Activities	-5.855M	-6.127M	-4.446M
Cash From Financing Activities	-100.0K	0.000	363.7M
Net Change In Cash	4.399M	-17.77M	321.1M
YoY Change	-113.17%	-105.53%	203.13%
FREE CASH FLOW
Cash From Operating Activities	$10.35M	-$11.64M	-$38.11M
Capital Expenditures	-$5.855M	-$4.914M	-$4.446M
Free Cash Flow	$16.21M	-$6.724M	-$33.66M
YoY Change	-195.19%	-80.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#FinancialServiceMember
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#FinancialServiceMember
CY2022Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001832466
CY2021	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-40295
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	ALIGNMENT HEALTHCARE, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5596242
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1100 W. Town and Country Road
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Orange
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92868
CY2022Q1	dei	City Area Code CityAreaCode	844
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	310-2247
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	ALHC
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	97000
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	187256693
CY2022Q1	us-gaap	Cash Cash	448835000
CY2021Q4	us-gaap	Cash Cash	466600000
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	119000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	111000
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	84527000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	58512000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	32829000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27747000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	566191000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	552859000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31747000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30358000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7354000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7853000
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	36345000
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	35116000
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4977000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4709000
CY2022Q1	us-gaap	Assets Assets	646614000
CY2021Q4	us-gaap	Assets Assets	630895000
CY2022Q1	alhc	Medical Expenses Payable Current MedicalExpensesPayableCurrent	154963000
CY2021Q4	alhc	Medical Expenses Payable Current MedicalExpensesPayableCurrent	125886000
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	16443000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	17431000
CY2022Q1	alhc	Accrued Compensation AccruedCompensation	23564000
CY2021Q4	alhc	Accrued Compensation AccruedCompensation	23928000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	194970000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	167245000
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	152256000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150620000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6103000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6975000
CY2022Q1	us-gaap	Liabilities Liabilities	353329000
CY2021Q4	us-gaap	Liabilities Liabilities	324840000
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187414057
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187414057
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187193613
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187193613
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	187000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	187000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	916594000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	888547000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-623511000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-582694000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	293270000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	306040000
CY2022Q1	us-gaap	Minority Interest MinorityInterest	15000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	15000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	293285000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	306055000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	646614000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	630895000
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	345292000
CY2021Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	267000000
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	234000
CY2021Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	82000
CY2022Q1	us-gaap	Revenues Revenues	345526000
CY2021Q1	us-gaap	Revenues Revenues	267082000
CY2022Q1	alhc	Medical Expenses MedicalExpenses	303758000
CY2021Q1	alhc	Medical Expenses MedicalExpenses	251095000
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74293000
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64914000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3950000
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3737000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	382001000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	319746000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36475000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-52664000
CY2022Q1	us-gaap	Interest Expense InterestExpense	4401000
CY2021Q1	us-gaap	Interest Expense InterestExpense	4248000
CY2022Q1	alhc	Other Non Operating Expense Income OtherNonOperatingExpenseIncome	-59000
CY2021Q1	alhc	Other Non Operating Expense Income OtherNonOperatingExpenseIncome	-38000
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4342000
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4210000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40817000
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56874000
CY2021Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1474000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2398000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-40817000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-56874000
CY2022Q1	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted	178874192
CY2021Q1	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted	154432027
CY2022Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	306055000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-40817000
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28047000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	293285000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30611000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-56874000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	361601000
CY2021Q1	alhc	Stock Issued During Period Value To The Third Party Business Providers StockIssuedDuringPeriodValueToTheThirdPartyBusinessProviders	6480000
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	11510000
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	354252000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-40817000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-56874000
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	53000
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8000
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3993000
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3789000
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	566000
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	550000
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1070000
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1015000
CY2022Q1	alhc	Share Based Compensation And Common Stock Payments ShareBasedCompensationAndCommonStockPayments	28047000
CY2021Q1	alhc	Share Based Compensation And Common Stock Payments ShareBasedCompensationAndCommonStockPayments	20388000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	715000
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	648000
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26050000
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9326000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5079000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9547000
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	167000
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6000
CY2022Q1	alhc	Increase Decrease In Medical Expenses Payable IncreaseDecreaseInMedicalExpensesPayable	29077000
CY2021Q1	alhc	Increase Decrease In Medical Expenses Payable IncreaseDecreaseInMedicalExpensesPayable	16069000
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1656000
CY2021Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-298000
CY2022Q1	alhc	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-364000
CY2021Q1	alhc	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-3691000
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1026000
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-832000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11638000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38107000
CY2022Q1	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	1113000
CY2021Q1	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	850000
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	750000
CY2022Q1	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	750000
CY2021Q1	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	750000
CY2022Q1	alhc	Proceeds From Acquisition Of Property And Equipment ProceedsFromAcquisitionOfPropertyAndEquipment	-4914000
CY2021Q1	alhc	Proceeds From Acquisition Of Property And Equipment ProceedsFromAcquisitionOfPropertyAndEquipment	-4446000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6127000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4446000
CY2022Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0
CY2021Q1	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	1474000
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	390600000
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	25467000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	363659000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-17765000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	321106000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	468350000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207811000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	450585000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	528917000
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	2758000
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	2682000
CY2022Q1	alhc	Acquisition Of Property In Accounts Payable AcquisitionOfPropertyInAccountsPayable	331000
CY2021Q1	alhc	Acquisition Of Property In Accounts Payable AcquisitionOfPropertyInAccountsPayable	474000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	240000
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2022Q1	alhc	Common Stock Issuance Costs Included In Accounts Payable And Accrued Expenses CommonStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	0
CY2021Q1	alhc	Common Stock Issuance Costs Included In Accounts Payable And Accrued Expenses CommonStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	3532000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	448835000
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	528417000
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1750000
CY2021Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	500000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	450585000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	528917000
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9200000
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	0
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1045000
CY2022Q1	alhc	Number Of Consolidated Variable Interest Entities NumberOfConsolidatedVariableInterestEntities	3
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7838000
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements requires management to make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements. Our significant estimates include, but are not limited to, the determination of medical expenses payable; the impact of risk adjustment provisions related to our Medicare contracts; collectability of receivables; right of use (“ROU”) assets and lease liabilities valuation; valuation of related impairment recognition of long-lived assets, including goodwill and intangible assets; equity-based compensation expense; and contingent liabilities. Estimates and judgments are based upon historical information and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates and the impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.</span></p>
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	345292000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	267000000
CY2022Q1	alhc	Schedule Of Property And Equipment Estimated Useful Lives Table Textblock ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextblock	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is computed using the straight-line method generally based on the following estimated useful lives:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:72.209%;"/> <td style="width:1.639%;"/> <td style="width:26.153%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Estimated Service Lives (years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Computer and equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Office equipment and furniture</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15 (or lease term, if shorter)</span></span></p></td> </tr> </table>
CY2021Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	19685000
CY2022Q1	alhc	Pharmacy Rebates PharmacyRebates	-43931000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16209312
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12640391
CY2022Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2547000
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2446000
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	152256000
CY2022Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	153669000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	150620000
CY2021Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	154367000
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022Q1	us-gaap	Government Contract Receivable GovernmentContractReceivable	36575000
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash deposits and restricted investments with financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to certain limits. At March 31, 2022 and December 31, 2021, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">here was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">447,711</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">465,824</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in excess of FDIC-insured limits.</span></p>
CY2022Q1	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	447711000
CY2021	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	465824000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P4Y
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-40817000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-56874000
CY2022Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	187091570
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	165611120
CY2022Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	8217378
CY2021Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	11179093
CY2022Q1	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted	178874192
CY2021Q1	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted	154432027
CY2022Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2021Q4	alhc	Pharmacy Rebates PharmacyRebates	-34376000
CY2022Q1	us-gaap	Other Receivables OtherReceivables	4140000
CY2021Q4	us-gaap	Other Receivables OtherReceivables	4562000
CY2022Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	84646000
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	58623000
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	119000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	111000
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	84527000
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	58512000
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	53000
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	8000
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	123810000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	118560000
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92063000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	88202000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31747000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30358000
CY2022Q1	us-gaap	Depreciation Depreciation	3896000
CY2021Q1	us-gaap	Depreciation Depreciation	3707000
CY2022Q1	us-gaap	Goodwill Gross GoodwillGross	30629000
CY2022Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0
CY2022Q1	us-gaap	Goodwill Goodwill	30629000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	39296000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2951000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	36345000
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	29303000
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0
CY2021Q4	us-gaap	Goodwill Goodwill	29303000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	37970000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2854000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	35116000
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	289000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	226000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	82000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	60000
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	60000
CY2022Q1	alhc	Finite Lived Intangible Asset Expected Amortization Thereafter FiniteLivedIntangibleAssetExpectedAmortizationThereafter	82000
CY2022Q1	alhc	Estimated Amortization Expense Related To Intangible Assets EstimatedAmortizationExpenseRelatedToIntangibleAssets	799000
CY2021Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table is a detail of medical expenses payable as of March 31, 2022 and December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.735%;"/> <td style="width:1.614%;"/> <td style="width:1.206%;"/> <td style="width:12.82%;"/> <td style="width:0.993%;"/> <td style="width:1.614%;"/> <td style="width:1.206%;"/> <td style="width:12.82%;"/> <td style="width:0.993%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">March 31,<br/>2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Claims incurred but not paid</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">84,883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">77,073</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Capitation payable, risk-sharing payable, and other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">70,080</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">48,813</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">154,963</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">125,886</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	84883000
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	77073000
CY2022Q1	alhc	Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther	70080000
CY2021Q4	alhc	Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther	48813000
CY2022Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	154963000
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	125886000
CY2022Q1	alhc	Remaining Claim Amounts Payment Period RemainingClaimAmountsPaymentPeriod	P3Y
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	77073000
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	82391000
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	103625000
CY2021Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	83223000
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-9521000
CY2021Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-3745000
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	94104000
CY2021Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	79478000
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	37626000
CY2021Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	22746000
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	48668000
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	84883000
CY2021Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	57786000
CY2021Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	81337000
CY2022Q1	alhc	Liability For Claims And Claims Other Medical Expenses Payable LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable	70080000
CY2022Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	86294000
CY2021Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	80532000
CY2021Q1	alhc	Liability For Claims And Claims Other Medical Expenses Payable LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable	47336000
CY2022Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	154963000
CY2021Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	128673000
CY2022Q1	alhc	Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense	5875000
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	155182000
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	154112000
CY2022Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2926000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3492000
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	152256000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	150620000
CY2022Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	152256000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150620000
CY2022Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	155182000
CY2022Q1	alhc	Debt Instrument Principal Balance Outstanding DebtInstrumentPrincipalBalanceOutstanding	135000000
CY2022Q1	alhc	Long Term Debt Commitment Fee LongTermDebtCommitmentFee	6750000
CY2022Q1	alhc	Debt Instrument Payment In Kind Interest On Principal Balance DebtInstrumentPaymentInKindInterestOnPrincipalBalance	13093000
CY2022Q1	alhc	Debt Instrument Payment In Kind Interest On Principal Balance Commitment Fee DebtInstrumentPaymentInKindInterestOnPrincipalBalanceCommitmentFee	339000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10938521
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.02
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1269156
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.95
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	18.02
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11925082
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.05
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y10D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2896000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2633227
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	18.00
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y11M1D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2022Q1	alhc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	5114000
CY2021Q1	alhc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	83982000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	22668
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	282595
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28047000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31787000
CY2022Q1	alhc	Description Of Tangible Net Equity Requirement DescriptionOfTangibleNetEquityRequirement	The required amount is the larger of: (1) $1,000; (2) 2% of the first $150,000 of annualized premium revenue, plus 1% of annualized premium revenue in excess of $150,000; or (3) 8% of the first $150,000 of annualized health care expenditures, except for those paid on a capitated or managed hospital payment basis, plus 4% of the annualized health care expenditures in excess of $150,000, except those paid on a capitated or managed hospital payment basis, plus 4% of annualized hospital expenditures paid on a managed hospital payment basis. We were in compliance with the TNE requirement for all periods presented.
CY2022Q1	alhc	Tangible Net Equity Required Amount TangibleNetEquityRequiredAmount	1000000
CY2022Q1	alhc	Annualized Premium Revenue Percentage AnnualizedPremiumRevenuePercentage	0.02
CY2022Q1	us-gaap	Tangible Capital Required For Capital Adequacy TangibleCapitalRequiredForCapitalAdequacy	150000000
CY2022Q1	alhc	Annualized Premium Revenue Excess Amount Percentage AnnualizedPremiumRevenueExcessAmountPercentage	0.01
CY2022Q1	alhc	Annualized Health Care Expenditures Percentage AnnualizedHealthCareExpendituresPercentage	0.08
CY2022Q1	alhc	Annualized Health Care Expenditures Excess Amount Percentage AnnualizedHealthCareExpendituresExcessAmountPercentage	0.04
CY2022Q1	alhc	Annualized Hospital Expenditure Paid Percentage AnnualizedHospitalExpenditurePaidPercentage	0.04
CY2021Q4	alhc	Amounts Accrued For Legal Proceedings AmountsAccruedForLegalProceedings	0
CY2022Q1	alhc	Amounts Accrued For Legal Proceedings AmountsAccruedForLegalProceedings	0

Files In Submission

Name	View Source	Status
0000950170-22-007889-index-headers.html	Edgar Link	pending
0000950170-22-007889-index.html	Edgar Link	pending
0000950170-22-007889.txt	Edgar Link	pending
0000950170-22-007889-xbrl.zip	Edgar Link	pending
alhc-20220331.htm	Edgar Link	pending
alhc-20220331.xsd	Edgar Link	pending
alhc-20220331_cal.xml	Edgar Link	unprocessable
alhc-20220331_def.xml	Edgar Link	unprocessable
alhc-20220331_htm.xml	Edgar Link	completed
alhc-20220331_lab.xml	Edgar Link	unprocessable
alhc-20220331_pre.xml	Edgar Link	unprocessable
alhc-ex10_1.htm	Edgar Link	pending
alhc-ex31_1.htm	Edgar Link	pending
alhc-ex31_2.htm	Edgar Link	pending
alhc-ex32_1.htm	Edgar Link	pending
alhc-ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALHC
Alignment Healthcare, Inc. Stock $alhc

2022 Q2 Form 10-Q Financial Statement

#000095017022007889 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALHC Alignment Healthcare, Inc. Stock $alhc

2022 Q2 Form 10-Q Financial Statement

#000095017022007889 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALHC
Alignment Healthcare, Inc. Stock $alhc